In the open-label FIBROMET trial, metformin treatment was associated with reductions in bone marrow fibrosis and downregulation of key oncogenic signaling pathways in patients wit ...

JAK inhibitors like baricitinib, ritlecitinib, and brepocitinib show promise in treating alopecia areata, with baricitinib approved by FDA and EMA. Baricitinib significantly reduced SALT scores at 24 ...

Arash Mostaghimi, MD, MPA, MPH, director of the inpatient dermatology consult service at Brigham & Women's Hospital, discusses the utility of deuruxolitinib for treating moderate to severe alopecia ...

Sepsis is a complex clinical syndrome characterized by dysregulated immune responses, systemic inflammation, and multi-organ dysfunction. It involves intricate interactions among multiple signaling ...

PARIS — Long-term results from the ALLEGRO clinical trial program of Pfizer’s JAK inhibitor ritlecitinib for severe alopecia areata showed that complete scalp regrowth occurred in a good proportion of ...

PARIS — In a study that employed change in inflammatory biomarkers as a primary endpoint, hair regrowth with ritlecitinib, a dual JAK3/TEC inhibitor, was observed across three types of cicatricial ...

Leveraging advanced spatial proteomics, scientists have identified the JAK/STAT pathway as a critical target for treating toxic epidermal necrolysis, offering new hope for patients with this ...